A 2013 study on 226 patients with metastatic colorectal cancer (mCRC) treated with cetuximab showed that high EphA2 mRNA receptor expression was an independent prognostic factor for poor outcome while low levels of the EphA2 mRNA were associated with objective response (OR) to cetuximab [61]. Here, EPHA2 is linked to metastatic colorectal cancer.